Multiple Sclerosis Society of Canada have given CA$400,000 (about $312,500) to support a pilot clinical trial investigating the potential of metformin, a common diabetes therapy, to treat children and young adults with multiple sclerosis (MS). The Phase 1/2 feasibility trial (NCT04121468) is recruiting up to 30 patients, ages 10 to 25, at two sites in Toronto. Those interested may find additional information here. MS is an autoimmune disease characterized by the damage and loss of…

You must be logged in to read/download the full post.